Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
PE Hall, P Schmid - Breast Cancer Research and Treatment, 2022 - Springer
Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.
PE Hall, P Schmid - Breast Cancer Research and Treatment, 2022 - europepmc.org
Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
PE Hall, P Schmid - Breast cancer research and treatment, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
PE Hall, P Schmid - Breast Cancer Research and Treatment, 2022 - search.proquest.com
Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …